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Abstract
Introduction: It is debated whether early trauma-induced coagulopathy (TIC) in severely injured patients reflects
disseminated intravascular coagulation (DIC) with a fibrinolytic phenotype, acute coagulopathy of trauma shock
(ACoTS) or yet other entities. This study investigated the prevalence of overt DIC and ACoTS in trauma patients
and characterized these conditions based on their biomarker profiles.
Methods: An observational study was carried out at a single Level I Trauma Center. Eighty adult trauma patients
(≥18 years) who met criteria for full trauma team activation and had an arterial cannula inserted were included.
Blood was sampled a median of 68 minutes (IQR 48 to 88) post-injury. Data on demography, biochemistry, injury
severity score (ISS) and mortality were recorded. Plasma/serum was analyzed for biomarkers reflecting tissue/
endothelial cell/glycocalyx damage (histone-complexed DNA fragments, Annexin V, thrombomodulin, syndecan-1),
coagulation activation/inhibition (prothrombinfragment 1+2, thrombin/antithrombin-complexes, antithrombin,
protein C, activated protein C, endothelial protein C receptor, protein S, tissue factor pathway inhibitor, vWF), factor
consumption (fibrinogen, FXIII), fibrinolysis (D-dimer, tissue-type plasminogen activator, plasminogen activator
inhibitor-1) and inflammation (interleukin (IL)-6, terminal complement complex (sC5b-9)). Comparison of patients
stratified according to the presence or absence of overt DIC (International Society of Thrombosis and Hemostasis
(ISTH) criteria) or ACoTS (activated partial thromboplastin time (APTT) and/or international normalized ratio (INR)
above normal reference).
Results: No patients had overt DIC whereas 15% had ACoTS. ACoTS patients had higher ISS, transfusion
requirements and mortality (all P < 0.01) and a biomarker profile suggestive of enhanced tissue, endothelial cell
and glycocalyx damage and consumption coagulopathy with low protein C, antithrombin, fibrinogen and FXIII
levels, hyperfibrinolysis and inflammation (all P < 0.05). Importantly, in non-ACoTS patients, apart from APTT/INR,
higher ISS correlated with biomarkers of enhanced tissue, endothelial cell and glycocalyx damage, protein C
activation, coagulation factor consumption, hyperfibrinolysis and inflammation, that is, resembling that observed in
patients with ACoTS.
Conclusions: ACoTS and non-ACoTS may represent a continuum of coagulopathy reflecting a progressive early
evolutionarily adapted hemostatic response to the trauma hit and both are parts of TIC whereas DIC does not
appear to be part of this early response.
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Trauma is a major cause of death and disability world-
wide [1], and since hemorrhage accounts for approxi-
mately 40% of all trauma fatalities. this is a leading
cause of potentially preventable deaths [2]. When death
is not immediately due to exsanguination, bleeding and
prolonged shock increase the risk of multiple organ fail-
ure and late mortality [2,3]. The exact mechanism(s)
responsible for death in trauma patients remain elusive
but much attention has been given to coagulopathy
since this is an independent predictor of mortality [4]
that is present already at the scene of an accident [5,6]
and upon arrival at the emergency department [7,8].
Different drivers of trauma-induced coagulopathy
(TIC) have been proposed by different groups of
researchers [9]: Some advocate that TIC reflects dissemi-
nated intravascular coagulation (DIC) with a fibrinolytic
(hemorrhagic) phenotype based on the observation that
trauma DIC patients display prolonged prothrombin
time (PT), have low fibrinogen and antithrombin (AT)
levels early after injury and have high fibrin/fibrinogen
degradation products (FDP) and D-dimer levels indicat-
ing massive (uncontrolled) thrombin generation and acti-
vation (through the tissue-factor dependent coagulation
pathway) followed by extensive fibrin(ogen)olysis and
consumption coagulopathy [8,10,11]. Furthermore, they
infer that the higher FDP/D-dimer ratio and low fibrino-
gen levels result from fibrin(ogen)olysis caused by exces-
sive plasmin and neutrophil elastase production and
release, independent of hypoperfusion [11,12]. Contrary
to this view, Brohi and colleagues proposed that TIC, as
identified by a moderately prolonged activated partial
thromboplastin time (APTT), prothrombin time (PT) or
international normalized ratio (INR) [7,13] is driven by
the combination of trauma and shock and, importantly,
by the degree of tissue hypoperfusion (acute coagulopa-
thy of trauma shock, ACoTS) [14]. The underlying
mechanism is suggested to include enhanced early gen-
eration of activated factors, including thrombin that, due
to reduced thrombin clearance, results in increased
thrombin-thrombomodulin complex formation on adja-
cent endothelial cells and ensuing enhanced activation of
the anticoagulant protein C (PC) pathway with enhanced
PC activation. This leads to reduced thrombin genera-
tion, through inhibition of FV and FVIII, decreased fibri-
nogen utilization and enhanced fibrinolysis [4,14,15].
Importantly, they emphasize that microvascular throm-
bosis does not occur in trauma hemorrhage and that
there is a relative sparing of platelets and fibrinogen,
thereby making ACoTS a distinct clinical entity from the
DIC observed in, for example, sepsis and other disease
conditions classically associated with DIC [4].
Common for both models presented above, however,
is that only the fluid phase of the hemostatic system or,
more correctly, only the concentrations of different ele-
ments in the plasma fraction of the fluid phase, has
been investigated. We recently suggested that the state
of the fluid phase including its cellular elements, that is,
circulating whole blood, is a consequence of the degree
of the tissue injury and, importantly, is critically related
to the degree of endothelial damage, with a progressively
more procoagulant endothelium inducing a gradient of
increasing anticoagulation towards the fluid phase [16].
In alignment with this, we found that in trauma patients
upon hospital admission, a high level of syndecan-1, a
marker of endothelial glycocalyx degradation, was asso-
ciated with high sympathoadrenal activity and increased
mortality, even after adjusting for injury severity score
[17]. Also, only in patients with high syndecan-1 levels
was increasing injury severity associated with increased
tissue and endothelial damage, protein C depletion,
hyperfibrinolysis and inflammation [17].
The aim of the present study was, therefore, to inves-
tigate the prevalence of DIC and ACoTS, respectively, in
trauma patients upon admission to our Level I Trauma
Center and to characterize these conditions based on
their biomarker profiles to delineate differences in asso-
ciation between the trauma hit (injury severity, shock)
and biomarkers of tissue injury, endothelial and glycoca-
lyx damage, thrombin generation and factor depletion,
fibrinolysis and inflammation. Here we report that no
trauma patients with blood sampled approximately one
hour post-injury had overt DIC, whereas 15% had
ACoTS defined as moderately increased APTT and/or
INR. Furthermore, ACoTS patients and non-ACoTS
patients displayed a comparable biomarker profile with
increasing injury severity indicating that these condi-
tions represent a continuum of coagulopathy reflecting a
progressive early evolutionarily adapted hemostatic
response to the trauma hit and both are parts of TIC,
whereas DIC does not appear to be part of this early
response.
Materials and methods
Study design
This was an observational cohort study of trauma
patients admitted directly to a Level I Trauma Center at
a tertiary hospital (Rigshospitalet, Copenhagen, Den-
mark, covering 2.5 million inhabitants) between March
2010 and November 2010. The study is part of an
ongoing larger international multicenter study, Activa-
tion of Coagulation and Inflammation after Trauma 3
(ACIT3), approved by the Regional Ethics Committee
(H-4-2009-139), the Danish Data Protection Agency and
conducted in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from the
patients or next of kin. Here we report on the findings
related to a cohort of 80 patients recruited from the
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ments of an extensive number of biomarkers with
ELISA kits that each provide analysis of 80 samples.
Patient selection
ACIT3 study inclusions were as follows: adult trauma
patients (≥18 years) who met criteria for full trauma
team activation (based on the mechanism of injury or
physiologic or anatomic injury criteria) and had an
arterial cannula. The latter was chosen since only
patients with expected severe injuries have an arterial
cannula placed immediately upon hospital admission.
Exclusion criteria were arrival in the Trauma Center > 2
hours after injury; > 2, 000 ml of intravenous fluids
administered before hospital arrival; transfer from
another hospital and burns > 5% total body surface area.
Patients were retrospectively excluded if they were tak-
ing anticoagulant/antiplatelet medications (except
aspirin), had moderate or severe liver disease or had
known bleeding diathesis.
The 80 included patients were selected from the first
100 patients recruited to the ACIT3 study with complete
data. We intended to include 80 patients because we mea-
sured an extensive number of biomarkers by ELISA, with
each ELISA kit providing analysis of 80 samples. We
aimed at including the most severely injured and/or coa-
gulopathic patients and selected the 80 patients according
to: outcome (mortality or intensive care unit (ICU) admis-
sion post trauma; yes), transfusion of red blood cells
(RBC) within six hours (yes), Revised Trauma Score (RTS)
(< 5.00, we had no access to Injury Severity Score (ISS)
until later in the study period) or coagulopathy (APTT
≥35 sec, INR ≥1.2, Ly30 > 1%/Cl30 < 95%; yes). This
yielded 70 severely injured/coagulopathic patients, and
additionally 10 patients (aged 48 years (IQR 43 to 52), 60%
males) were selected blinded from the remaining 30 and
so on). The 20 patients not included in this study, had,
compared to the included patients, comparable age and
gender (41 years (IQR 33 to 53), 40% males) and APTT
(26 (IQR 23 to 27), NS) but had, as expected, lower ISS (4
(IQR 2 to 10), P < 0.001), mortality (0%, P = 0.037) and
INR (1.1 (IQR 1.0 to 1.1), P = 0.007). Two of the 20
patients not included had a hypercoagulable Thrombelas-
tography (TEG) (maximal amplitude (MA) > 69, 10%).
Data on demography, clinical and biochemical para-
meters, investigations, management and 30-day mortality
were recorded and ISS scores were obtained from the
Trauma Audit & Research Network (TARN) database.
No patients received tranexamic acid, adrenaline or
noradrenaline prior to blood sampling.
DIC and ACoTS criteria
Overt DIC was defined [18] and modified [19] according
to the International Society of Thrombosis and
Hemostasis (ISTH) criteria, with the following cut off
values: I) Platelet counts < 50 *10
9/L (two points), 50 to
100 *10
9/l (one point); II) Fibrinogen < 1 g/l (one
point); III) D-dimer > 4 mg/l (three points), 0.39 to 4.00
mg/l (two points) and IV) INR (PT is not available at
our hospital) > 2.3 (two points), 1.4 to 2.3 (one point).
Overt DIC was diagnosed as a sum of five or more
points. ACoTS was diagnosed as APTT and/or INR
above normal reference, that is, > 35 sec or > 1.2 ratio,
respectively, in accordance with previous studies
[17,20,21].
Blood sampling
Blood was sampled immediately upon arrival for stan-
dard arterial blood gas (ABG, Radiometer ABL 725/735,
Radiometer AS, Bronshøj,), routine biochemistry and
research analyses (citrate, heparin, EDTA plasma,
serum). Routine biochemistry samples were analyzed in
a DS/EN ISO 15189 standardized laboratory by a Sys-
mex XE-2100, Sysmex Europe GmbH, Norderstedt, Ger-
many (hemoblobin, platelets, leukocytes) and ACL TOP
(APTT, INR, AT, fibrinogen). Plasma samples were ice-
cooled immediately whereas serum samples were kept at
room temperature (RT) for 1 h before centrifugation
(one (serum) or two (plasma) times 1, 800 g at 5°C for
10 minutes) and storage at -80°C.
Enzyme linked immunosorbent assay (ELISA)
measurements
Soluble biomarkers of tissue, endothelial cell and glyco-
calyx damage, coagulation activation/inhibition and fac-
tor consumption, fibrinolysis and inflammation were
measured in uniplicate by commercially available immu-
noassays according to the manufacturer’s recommenda-
tions. In each patient, all 18 biomarkers were measured
corresponding to a total of 18*80 = 1, 440 measure-
ments, with no missing measurements. The biomarkers
were analyzed in EDTA/citrate plasma or serum as fol-
lows: EDTA plasma: histone-complexed DNA fragments
(hcDNA, Cell Death Detection ELISA
PLUS,R o c h e ,H v i -
dovre, Denmark; LLD not stated, relative quantification);
Annexin V (American Diagnostica Inc. (ADI), Stamford,
CT, USA; LLD not stated, normal reference < 10 ng/
ml); soluble thrombomodulin (sTM) (Nordic Biosite,
Copenhagen, Denmark; LLD 0.38 ng/ml) and D-dimer
(ADI; LLD 2-4 ng/ml). Citrate plasma: protein C (PC,
Helena Laboratories, Beaumont, TX, USA; LLD 5% of
reference plasma); activated protein C (APC, USCN-
LIFE; LLD 4.2 pg/ml); soluble endothelial protein C
receptor (sEPCR, R&D Systems Europe, Abingdon, UK;
LLD 0.064 ng/ml); protein S (PS, ADI; LLD not stated,
quantified relative to provided reference plasma); tissue-
type plasminogen activator (tPA, ADI, detects sc-tPA,
tc-tPA and tPA/plasminogen activator inhibitor (PAI)-1
Johansson et al. Critical Care 2011, 15:R272
http://ccforum.com/content/15/6/R272
Page 3 of 10complexes; LLD 1 ng/ml); plasminogen activator inhibi-
tor-1 (PAI-1, Assaypro, St. Charles, MO, USA; LLD 0.2
ng/ml); prothrombinfragment 1 and 2 (PF1.2, USCN-
LIFE; LLD 0.043 nmol/l); thrombin/antithrombin com-
plex (TAT, USCNLIFE, Wuhan EIAab Science Co,
Wuhan, China; LLD 0.215 ng/ml); tissue factor pathway
inhibitor (TFPI, ADI, detects intact TFPI, truncated
TFPI, TF/FVIIa/TFPI complexes; LLD 0.18 ng/ml); von
Willebrand Factor antigen (vWF, Helena Laboratories,
LLD 5% of reference plasma); factor XIII (FXIII, Assay-
pro; LLD 50 pg/ml); terminal complement complex
(sC5b-9, MicroVue sC5b-9 plus EIA Kit, Quidel Corp.,
San Diego, CA, USA; LLD 3.7 ng/ml) and interleukin-6
(IL-6, Quantikine HS, R&D Systems Europe; LLD 0.039
pg/ml). Serum: Syndecan-1 (Diaclone SAS, Besancon,
France; LLD 2.56 ng/ml).
Statistics
Statistical analysis was performed using SAS 9.1 (SAS
Institute Inc., Cary, NC, USA). Data from patients strati-
fied according to presence (n =1 2 )o ra b s e n c e( n =6 8 )
of ACoTS were compared by Wilcoxon Rank Sum tests
and Chi-square/Fischer exact tests, as appropriate and
this comparison was performed both on the full cohort
of patients and after excluding patients with sTBI. Cor-
relations were investigated by Spearman correlations,
presented by rho and P-values. Data are presented as
medians with interquartile ranges (IQR). P-values < 0.05
were considered significant.
Results
Study patients
The present study included 80 trauma patients with ISS
in the entire range (ISS > 26 n = 23, 15 to 26 n =2 6 ,
and < 15 n = 30) and with demography, injury severity,
biochemistry, coagulopathy and mortality as displayed in
T a b l e1 .M o s tp a t i e n t s( 9 6 % )w e r er e f e r r e db ym o b i l e
emergency care units (MECU) staffed with anesthetists
(28% by helicopter) and blood samples were drawn a
median of 68 minutes (IQR 48 to 88) after the injury.
Eleven patients (14%) received massive transfusion (> 10
RBC the initial 24 hours) and overall 30-day mortality
was 18% (n = 14) (Table 1).
Trauma DIC
No patients had overt DIC according to the ISTH cri-
teria [18,19] since only one patient had platelets
between 50 and 100 *10
9/l (one point), one patient had
fibrinogen < 1 g/l (one point), no patients had D-dimer
> 0.39 mg/l and four patients had INR between 1.4 and
2.3 (one point). No patients had more than one concur-
rent abnormal parameter so no patients scored more
than one point. No attempts were made to stratify
patients to compare these according to DIC criteria.
Biomarker profile in patients with ACoTS
Twelve patients (15%) had ACoTS defined as APTT or
INR above normal reference level [17,20,21] (Table 1).
When comparing patients with or without ACoTS,
those demonstrating ACoTS had a higher degree of tis-
sue injury (higher ISS, hcDNA, Annexin V) and shock
(lower pH and SBE), lower pre-hospital Glascow Coma
Score (GCS), hemoglobin (P = 0.055), higher transfusion
requirements and a four-fold increased mortality (Table
2). Patients with ACoTS also had higher sTM, synde-
can-1, D-dimer and IL-6 but lower AT, PC, fibrinogen
and FXIII levels indicative of enhanced endothelial cell
and glycocalyx damage, factor consumption, hyperfibri-
nolysis and inflammation, respectively, and they had a
tendency towards lower thrombin generation (PF1.2)
and lower sEPCR and PS (Table 2).
Though the proportion of patients with sTBI was
comparable in ACoTS and non-ACoTS patients (Table
2), we investigated whether sTBI confounded the
observed differences between ACoTS and non-ACoTS
patients by excluding sTBI patients before the compari-
son, because it is widely debated whether sTBI may
directly drive coagulopathy in trauma patients. When
comparing the 9 ACoTS and 39 non-ACoTS patients
without sTBI, these patients displayed the same
Table 1 Demography, injury severity, biochemistry,
hemostasis, transfusion requirements and mortality in
the 80 trauma patients investigated
Patients
N 80
Age yrs 46 (33 to 64)
Gender m% 68% (54)
Blunt trauma % (n) 91% (73)
ISS score 17 (10 to 28)
sTBI % (n) 31% (22)
GCS (PH) score 13 (6 to 15)
pH 7.34 (7.29 to 7.39)
SBE mmol/l -2.0 (-4.0 to 0.0)
Lactate mmol/l 1.7 (1.2 to 2.7)
SatO2 (PH) % 98 (93 to 100)
Shockindex (PH) HR/SBP 0.62 (0.50 to 0.75)
Hemoglobin mmol/l 8.4 (7.3 to 9)
Platelet count 10
9/l 208 (173 to 253)
APTT > 35 sec % 8% (6)
INR > 1.2 % 13% (10)
Saline (PH) ml 350 (0 to 1, 000)
MT (> 10 RBC in 24 h) % (n) 14% (11)
Mortality % (n) 18% (14)
Data are presented as medians (IQR) or n (%).
APTT, activated partial thromboplastin time; GCS, Glascow Coma Score scale;
INR, international normalized ratio; ISS, injury severity score; MT, > 10 RBC the
initial 24 hours; PH, pre-hospital at the site of injury; RBC, red blood cells; sTBI,
severe Traumatic Brain Injury, Abbreviated Injury Score head > 3
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and non-ACoTS patients
ACoTS Normal
(no ACoTS)
p to value
Demography
N 12 68
Age yrs 42 (26 to 74) 46 (34 to 63) NS
Gender m% (n) 75% (9) 66% (45) NS
Blunt trauma % (n) 92% (11) 91% (62) NS
ISS score 34 (30 to 43) 17 (10 to 25) < 0.001
sTBI % (n) 25% (3) 32% (19) NS
GCS (PH) score 3 (3 to 7) 13 (7 to 15) < 0.001
Shockindex (PH) HR/SBP 0.68 (0.56 to 0.78) 0.61 (0.48 to 0.75) NS
RBC 1 h n 5 (0 to 9) 0 (0 to 0) < 0.001
MT (> 10 RBC in 24 h) % (n) 50% (6) 7% (5) < 0.001
Mortality % (n) 50% (6) 12% (8) 0.001
Shock, biochemistry and coagulopathy
pH 7.27 (7.13 to 7.31) 7.36 (7.31 to 7.40) 0.001
SBE mmol/l -5.1 (-8.2 to -2.35) -1.8 (-3.4 to 0.0) 0.009
Hemoglobin mmol/l 6.8 (5.8 to 8.8) 8.5 (7.6 to 9.0) 0.055
Platelet count 10
9/l 197 (173 to 238) 208 (176 to 259) NS
Fibrinogen g/l 1.53 (1.25 to 2.02) 2.45 (2.18 to 2.89) 0.001
FXIII microg/ml 23 (17 to 29) 30 (24 to 39) 0.004
vWF % 143 (100 to 209) 201 (140 to 226) 0.117
APTT sec 33 (27 to 42) 25 (23 to 26) NA
INR ratio 1.3 (1.3 to 1.5) 1.1 (1.1 to 1.1) NA
Tissue, endothelial cell and glycocalyx injury
Histone-complexed DNA % 15.4 (8.5 to 58.2) 4.8 (0.1 to 11.8) 0.003
Annexin V ng/ml 45 (40 to 61) 24 (21 to 35) 0.001
sTM ng/ml 2.90 (2.27 to 4.09) 1.43 (0.92 to 3.34) 0.015
Syndecan-1 ng/ml 62 (34 to 107) 31 (18 to 48) 0.013
Thrombin generation
PF1.2 nmol/l 3.17 (0.61 to 16.03) 6.71 (2.08 to 18.79) 0.120
TAT ng/ml 38 (36 to 41) 36 (30 to 43) NS
Natural anticoagulation
AT 10
3 U/l 0.68 (0.62 to 0.85) 0.95 (0.87 to 1.03) < 0.001
PC % 72 (60 to 89) 114 (99 to 129) < 0.001
APC ng/ml 9.98 (8.59 to 11.96) 9.78 (7.72 to 12.15) NS
sEPCR ng/ml 174 (141 to 242) 230 (175 to 398) 0.087
PS % 57 (50 to 69) 66 (61 to 71) 0.078
TFPI ng/ml 63 (43 to 74) 60 (47 to 80) NS
Fibrinolysis
D-dimer ng/ml 174 (173 to 176) 158 (122 to 173) 0.001
tPA ng/ml 7.2 (5.5 to 11.8) 6.9 (3.5 to 12.6) NS
PAI ng/ml 26 (11 to 37) 22 (14 to 40) NS
Inflamamtion
sC5b-9 ng/ml 1, 014 (701 to 1, 173) 1, 027 (905 to 1, 232) NS
IL-6 pg/ml 110 (98 to 128) 61 (18 to 118) 0.024
Data are presented as medians (IQR) or n (%), with P-values shown for variables with P < 0.200, and in bold for P < 0.050. Patients with or without ACoTS were
compared by Wilcoxon Rank Sum tests or Chi-square/Fischer exact tests, as appropriate.
APTT, activated partial thromboplastin time; GCS, Glascow Coma Score scale; INR, international normalized ratio; ISS, injury severity score; MT, > 10 RBC the initial
24 hours; RBC, red blood cells; sTBI, severe Traumatic Brain Injury, Abbreviated Injury Score head > 3; PH, pre-hospital at the site of injury.
Biomarker abbreviations, see Materials and methods section, ELISA and the List of abbreviations.
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marker profiles as those described for ACoTS and non-
ACoTS patients in the full cohort. Thus, ACoTS/non-
sTBI patients still had significantly higher ISS, transfu-
sion requirements, mortality, enhanced shock (lower
pH, SBE) and a biomarker profile indicative of enhanced
tissue injury (higher hcDNA, Annexin V), factor con-
sumption and bleeding (lower AT, PC, fibrinogen, FXIII,
hemoglobin) and hyperfibrinolysis (D-dimer) (all P <
0.05) and thrombin generation remained borderline sig-
nificantly reduced in ACoTS/non-sTBI patients (P =
0.125). In contrast to the finding in the full cohort, syn-
decan-1 and sTM were only borderline significantly
increased in ACoTS/non-sTBI patients (P = 0.118 and P
= 0.086), which is probably due to a reduction in power
following exclusion of 31% of the patients rather than
due to a biologically relevant difference.
Injury severity, shock and biomarkers in ACoTS
Since trauma and shock are proposed drivers of ACoTS,
we looked for differences in associations between ISS or
SBE and the investigated biomarkers in patients with or
without ACoTS.
With regards to ISS, Activated Protein C correlated
positively with ISS in non-ACoTS (rho = 0.41, P =
0.001) but tended to correlate negatively in ACoTS (rho
= -0.43, P = 0.161) patients. Likewise, PF1.2 tended to
correlate positively with ISS in non-ACoTS (rho = 0.22,
P = 0.076) but negatively in ACoTS (rho = -0.52, P =
0.086). Furthermore, only in non-ACoTS patients,
higher ISS correlated positively with hcDNA, sTM, syn-
decan-1 (all P < 0.001), tPA (P = 0.026), D-dimer (P <
0.001) and IL-6 (P < 0.001) but negatively with AT (P =
0.018), fibrinogen (P = 0.009) and FXIII (P = 0.001)
indicating that increasing injury severity in non-ACoTS
patients was associated with a biomarker profile sugges-
tive of some degree of TIC with protein C activation,
coagulation factor consumption, hyperfibrinolysis and
inflammation.
With regards to Standard Base Excess (SBE), Protein
C and SBE correlated strongly positively in ACoTS (rho
=0 . 8 7 ,P < 0.001) whereas these only tended to corre-
late in non-ACoTS (rho = 0.21, P = 0.102). Activated
Protein C did not correlate with SBE in any of the
groups (data not shown). In non-ACoTS patients, SBE
correlated negatively with Annexin V (P = 0.003), synde-
can-1 (P = 0.004), D-dimer (P = 0.018) and IL-6 (P =
0.038) and positively with sEPCR (P = 0.029) (the latter
also observed in ACoTS patients, P = 0.039).
Fibrinogen and FXIII consumption
Given that ACoTS patients had low fibrinogen and
FXIII levels, we looked for differences in associations
between fibrinogen or FXIII and biomarkers of tissue
damage, thrombin generation and fibrinolysis in patients
with or without ACoTS. Notably, we found different
correlations between fibrinogen/FXIII and hcDNA,
PF1.2, Thrombin/antithrombin (TAT)-complexes and
D-dimer in ACoTS and non-ACoTS patients (Figure
1A-H) revealing negative correlations between FXIII and
hcDNA (Figure 1E) and D-dimer (Figure 1H) and posi-
tive correlations between fibrinogen and TAT (Figure
1C) only in ACoTS patients. Non-ACoTS patients dis-
played negative correlations between FXIII and biomar-
kers of thrombin generation (PF1.2, TAT, Figure 1F-G)
indicating that different mechanisms may contribute to
fibrinogen and FXIII consumption in patients with or
without ACoTS.
Discussion
In the present study, no patients had overt DIC accord-
ing to ISTH criteria whereas 15% had ACoTS, and these
patients had higher ISS, transfusion requirements and
mortality, and a biomarker profile indicative of
enhanced tissue, endothelial cell and glycocalyx damage,
and consumptive coagulopathy with low AT, PC, fibri-
nogen and FXIII levels, hyperfibrinolysis and inflamma-
tion. Importantly, in non-ACoTS patients, higher ISS
was associated with a biomarker profile indicative of
enhanced tissue, endothelial cell and glycocalyx damage
as well as an early hemostatic response/coagulopathy
characterized by protein C activation, coagulation factor
consumption, hyperfibrinolysis and inflammation sug-
gesting that TIC represents a continuum of hemostatic
response/coagulopathy dependent on the trauma hit and
its downstream effects.
Recently, it has been intensively debated whether the
early coagulopathy in severely injured patients reflects
DIC with a fibrinolytic (hemorrhagic) phenotype [8],
ACoTS [7,13] or yet other entities [9]. In the present
study, we compared the prevalence of DIC and ACoTS
in trauma patients admitted to our Level I Trauma Cen-
ter directly from the scene of accident with admission
blood samples taken approximately one hour post-injury
and found that no patients had overt DIC according to
ISTH criteria, whereas 15% had ACoTS. In accordance
with some studies [11,22,23], but in contrast to others
[15], patients with ACoTS had low fibrinogen and FXIII
levels indicative of consumption coagulopathy and in
ACoTS patients biomarkers of tissue damage (hcDNA),
low thrombin generation (TAT) and hyperfibrinolysis
(D-dimer) correlated with fibrinogen and FXIII con-
sumption. The finding that hcDNA correlated negatively
with coagulation factors in ACoTS patients is notable
given the recent finding that extracellular nucleic acids
can activate the contact activation (intrinsic) pathway
directly since it indicates that high levels of extracellular
nucleic acids derived from massive tissue and
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Figure 1 Correlations between fibrinogen or FXIII and different biomarkers in ACoTS or non-ACoTS patients. Correlations between
fibrinogen (A-D) or FXIII (E-H) and biomarkers of tissue damage (hcDNA), thrombin generation (PF1.2, TAT) and fibrinolysis (D-dimer) on
admission in 80 trauma patients stratified according to presence (ACoTS) or absence (no ACoTS) of ACoTS defined as APTT or INR above normal
reference (n = 12). Rho and P-values are shown for correlations between fibrinogen or FXIII and the mentioned variables in patients with ACoTS
(black circles, filled lines) or without ACoTS (white circles, dashed lines): A) log10 hcDNA (%) vs. fibrinogen (g/l), B) log10 PF1.2 (nmol/l) vs.
fibrinogen (g/l), C) Log10 TAT (ng/ml) vs. fibrinogen (g/l), D) Log10 D-dimer (ng/ml) vs. fibrinogen (g/l), E) log10 hcDNA (%) vs. FXIII (microg/ml), F)
log10 PF1.2 (nmol/l) vs. FXIII (microg/ml), G) Log10 TAT (ng/ml) vs. FXIII (microg/ml), H) Log10 D-dimer (ng/ml) vs. FXIII (microg/ml).
Johansson et al. Critical Care 2011, 15:R272
http://ccforum.com/content/15/6/R272
Page 7 of 10endothelial injuries may contribute significantly to coa-
gulation factor consumption [24]. Furthermore, the find-
ing that low SBE (shock) correlated strongly with low
PC in ACoTS patients is in alignment with the notion
that trauma-induced shock through hypoperfusion [15]
and/or enhanced catecholamine surge [20] contributes
to Protein C consumption probably through enhanced
endothelial thrombomodulin expression and/or high cir-
culating soluble thrombomodulin. The finding here of
increased circulating syndecan-1, a biomarker of glyco-
calyx degradation [25], in ACoTS patients probably
reflects more severe endothelial damage secondary to
the trauma and its downstream effects that may aug-
ment consumption of both fibrinogen and FXIII by pro-
moting a procoagulant endothelial surface and by
enhancing the shedding of thrombomodulin [26].
Thereby, enhanced glycocalyx degradation could be a
mechanistic difference between ACoTS defined by
increased APTT/INR as compared to non-ACoTS.
Thus, the coagulopathy in ACoTS may both reflect con-
sumption of coagulation factors critical for clot genera-
tion [27-29] and endogenous anticoagulation driven by
tissue injury, hyperfibrinolysis and/or shock (hypoperfu-
sion, catecholamines) [17,20,26].
An important finding in the present study was that
increasing ISS in patients without ACoTS (normal APTT/
INR) was associated with a response resembling that
described in patients with ACoTS [7,8,14,15,17,22,23], that
is, enhanced tissue, endothelial cell and glycocalyx damage,
protein C activation, factor and AT consumption, hyperfi-
brinolysis and inflammation. The lack of correlations
between ISS and INR/APTT in non-ACoTS patients, how-
ever, emphasizes that the complexity of TIC and/or the
hemostatic response to injury is not fully reflected by
plasma based coagulation tests. The finding of comparable
biomarker profiles in ACoTS and non-ACoTS patients
with increasing injury severity suggests that these condi-
tions may display a continuum of coagulopathy reflecting
a progressive early evolutionarily adapted hemostatic
response to the trauma hit with ACoTS probably repre-
senting an extreme response in patients with (from an
evolutionary point of view) non-survivable injuries (Figure
2). Furthermore, we hypothesize that both ACoTS and
non-ACoTS are part of TIC (Figure 2) which, based on
the biomarker profile, includes endothelial cell and glyco-
calyx damage, PC activation, coagulation factor and AT
consumption, hyperfibrinolysis and inflammation albeit
this needs to be confirmed in an independent cohort of
trauma patients of appropriate size. The discrepancy
between studies reporting DIC vs. ACoTS may obviously
reflect various methodological differences although we
infer that the timing of the blood sampling post-injury is a
critical factor since most studies reporting overt DIC in
trauma patients have collected admission blood samples
several hours (4 to 24 h) post-injury [11,12], whereas most
studies reporting of ACoTS have collected admission
blood samples much earlier (1 h or less post-injury)
[14,15,22,23]. Given the dynamic nature of the hemostatic
and inflammatory response to trauma [30], progression to
overt DIC post-injury may occur hours (but not immedi-
ately) after the injury, probably driven by a combination of
the tissue injury exerted by the initial trauma hit, systemic
endothelial dysfunction/damage, exhaustion of the natural
anticoagulant pathways and/or excessive inflammation
(Figure 2).
The results presented here are subject to the limita-
tions inherent to observationa ls t u d i e sa n d ,t h e r e b y ,d o
not allow independent evaluation of cause-and-effect
relationships. Furthermore, the low number of subjects
and especially the low number of both severely injured
patients and patients with ACoTS, included here
increases the risk of introducing a type II error,
emphasizing that the findings herein should be con-
firmed in a larger cohort of patients, and this is cur-
rently underway.
Conclusions
The present study found that no trauma patients with
blood sampled approximately one hour post-injury had
overt DIC, whereas 15% had ACoTS defined as moder-
ately increased APTT and/or INR. Though ACoTS
patients had higher ISS, transfusion requirements and
mortality and evidence of enhanced tissue, endothelial
cell and glycocalyx damage, consumptive coagulopathy,
hyperfibrinolysis and inflammation, non-ACoTS patients
displayed a comparable biomarker profile with increas-
ing injury severity. Based on these findings we infer that
ACoTS and non-ACoTS represent a continuum of coa-
gulopathy reflecting a progressive early evolutionarily
adapted hemostatic response to the trauma hit and both
are parts of TIC, whereas DIC does not appear to be
part of this early response.
Key messages
￿ It is debated whether severe tissue injury induces
an immediate disseminated intravascular coagulation
(DIC) or acute coagulopathy of trauma shock
(ACoTS, increased APTT and/or INR).
￿ In 80 adult trauma patients investigated approxi-
mately one hour post injury, no patient had overt
DIC (ISTH criteria), whereas 15% had ACoTS.
￿ ACoTS patients had higher ISS, transfusion
requirements and mortality, and a biomarker profile
suggestive of enhanced tissue, endothelial cell and
glycocalyx damage and consumption coagulopathy
with hyperfibrinolysis and inflammation, but non-
ACoTS patients displayed the same profile with
increasing ISS.
Johansson et al. Critical Care 2011, 15:R272
http://ccforum.com/content/15/6/R272
Page 8 of 10￿ Both ACoTS and non-ACoTS may represent a
continuum of coagulopathy that reflects an evolutio-
narily adapted hemostatic response to the trauma
hit.
￿ Both ACoTS and non-ACoTS are parts of trauma-
induced coagulopathy (TIC) whereas DIC does not
appear to be part of this early response.
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